Clear Search

Showing 1 result for “Winzenborg I”.

November 2019

Análisis de Exposición Respuesta de Eficacia y Seguridad de Upadacitinib en Estudios de Fase 2 y 3 para Apoyar la Evaluación de Riesgo Beneficio en la Artritis Reumatoide

Clin Pharmacol Ther . 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671.

UPA 15 mg provided the optimal benefit-risk in RA through maximizing efficacy with only small incremental benefit with 30 mg, and with consistency across RA subpopulations and with UPA monotherapy or combination with csDMARDs. Exposure-response analyses were conducted using combined data from two Phase 2b and five Phase 3 studies in order to characterise the relationship between plasma exposure and efficacy, as well as to select safety parameters using the totality of the data in subjects with R...